The 22nd European Hematology Association (EHA) Congress will be held in Madrid, Spain on June 22-25, 2017.

The educational and scientific program will cover current clinical practice, the latest findings in hematology research and more.

EHA 2017

22–25 June 2017 | Madrid, Spain

EHA 2017

22–25 June 2017 | Madrid, Spain

The 22nd European Hematology Association (EHA) Congress will be held in Madrid, Spain on June 22-25, 2017.

The educational and scientific program will cover current clinical practice, the latest findings in hematology research and more.

Moving in the right direction: new possibilities in lymphoma 1:27
Moving in the right direction: new possibilities in lymphoma
Wojciech Jurczak
Biosimilars: informing patients and physicians 0:39
Biosimilars: informing patients and physicians
Bertrand Coiffier
Navigating advances in the myeloma landscape over the past couple of years 1:59
Navigating advances in the myeloma landscape over the past couple of years
Saad Usmani
New targets in relapsed/refractory multiple myeloma patients 1:26
New targets in relapsed/refractory multiple myeloma patients
Sagar Lonial
Biosimilars in oncology: EHA 2017 session on rituximab 1:28
Biosimilars in oncology: EHA 2017 session on rituximab
Bertrand Coiffier • 22 Jun 2017
Why we need novel strategies for diffuse large B-cell lymphoma 3:27
Why we need novel strategies for diffuse large B-cell lymphoma
Bertrand Coiffier
Understanding biosimilars 2:40
Understanding biosimilars
Bertrand Coiffier • 22 Jun 2017
Towards a world without blood disorders 7:25
Towards a world without blood disorders
Tony Green
NEOD001: changing the treatment of amyloidosis 2:22
NEOD001: changing the treatment of amyloidosis
Morie Gertz
An update on kinase inhibitors from EHA 2017 2:02
An update on kinase inhibitors from EHA 2017
Barbara Eichhorst
Different is better: the fight against leukemia 4:38
Different is better: the fight against leukemia
Michaela Kotrová
Celebrating 60 years of successful allogeneic transplant at EHA 2017 3:51
Celebrating 60 years of successful allogeneic transplant at EHA 2017
Mohamad Mohty
Novel agents in multiple myeloma: considering toxicity and side effects 1:02
Novel agents in multiple myeloma: considering toxicity and side effects
Enrique Ocio
Getting specific with myeloma therapy: selecting the right treatments 1:30
Getting specific with myeloma therapy: selecting the right treatments
Saad Usmani
UKALL60+: identifying the standard of care for elderly patients with ALL 0:53
UKALL60+: identifying the standard of care for elderly patients with ALL
David Marks
Building genetic assessments into how we determine prognosis of ALL 0:49
Building genetic assessments into how we determine prognosis of ALL
David Marks
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals